AI 통합 혈액 분석기 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the AI-integrated blood analyzers market size is expected to increase from USD 1.07 billion in 2025 to USD 1.21 billion in 2026 and reach USD 2.30 billion by 2031, growing at a CAGR of 13.65% over 2026-2031.

This report is Segmented by Modality (Fully Automated Systems, POC Systems, and More), by Product Type (AI-Integrated Hematology Analyzers, AI-Integrated POC Blood Analyzers, and More), by Application (CBC Testing, and More), by End User (Hospitals, Diagnostic Laboratories, and More), and Geography (North America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).

Global AI-integrated Blood Analyzers Market Trends and Insights

Rising Demand for AI-Assisted Morphology Review

Manual peripheral blood smear review remains one of the slowest steps in laboratory hematology because it still depends heavily on trained staff and careful visual judgment. The studies indicated that this step can take 10-20 minutes per slide under manual review, while AI-assisted morphology platforms can cut that to under 5 minutes in suitable workflows. The same source reported that the CellaVision DM series delivered a 50% reduction in total smear analysis time with 92% preclassification accuracy, and the Sysmex DI-60 reduced hands-on time by more than 144 seconds per slide in prospective studies. In the AI-integrated blood analyzers market, time gain matters because it improves throughput without asking labs to add scarce morphology specialists. It also allows a pathologist or senior reviewer to oversee several sites from one location, which supports hub-and-spoke laboratory models that are becoming more common in large health systems. This is why the AI-integrated blood analyzers market is finding demand not only in major hospitals, but also in laboratory networks that need consistent review quality across urban and rural locations.

Expansion of Fully Automated High-Throughput Labs

The shift toward fully automated laboratory workcells continues to support the AI-integrated blood analyzers market because central laboratories need more throughput, better consistency, and fewer manual steps. Sysmex America introduced the next-generation XR-Series in May 2026 for high-complexity and high-volume laboratories, and the platform builds on the established XN-Series with higher throughput, enhanced AI analytics, and easier automation integration. The same direction is visible in mid-market automation, where Mindray and Inpeco signed a strategic cooperation agreement in June 2024 to connect hematology solutions with total laboratory automation systems and a broader in vitro diagnostics data architecture. The AI-integrated blood analyzers market benefits from this pattern because hospital systems are consolidating satellite laboratories into larger reference sites, and those sites need analyzer fleets that can handle more daily samples with fewer interruptions. Laboratory information system connectivity becomes more important under this model because high-volume sites want one workflow that links sample handling, analyzer output, digital morphology, and result release. As more laboratories standardize around integrated automation stacks, the AI-integrated blood analyzers market gains from replacement demand, software add-ons, and longer service relationships.

High Instrument and Per-Test Cost Burden

The AI-integrated blood analyzers market still faces a clear affordability barrier because full digital morphology capability, imaging hardware, software, and integration often require a level of spending that many smaller facilities cannot justify. The input notes that validated AI morphology platforms with high-resolution digital imaging and decision support software often carry list prices above USD 100,000. At the same time, reagent and per-test costs add recurring pressure on already tight laboratory budgets. This matters most in public systems and lower-tier facilities where reimbursement structures were built around conventional hematology testing rather than premium AI-enabled workflows. The AI-integrated blood analyzers market, therefore, risks splitting into two adoption tracks, with large reference laboratories moving faster while smaller and price-sensitive providers remain on older systems for longer. That split can slow total addressable demand even when the clinical case for automation is strong. It also increases pressure on vendors in the AI-integrated blood analyzer market to offer leasing, modular upgrades, or software overlays that lower the upfront hurdle.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Blood Disorder Screening Volumes
2. Decentralized Testing Needs in Acute and Urgent Care
3. Validation Gaps Versus Central Laboratory Standards

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Fully Automated Systems held 61.38% of the AI-integrated hematology blood market share in 2025 because large hospital laboratories and reference centers already depend on these platforms for high daily sample volumes. Their position is reinforced by laboratory consolidation, because larger centralized sites prefer workcells that can process thousands of samples with fewer manual steps and fewer interruptions. These systems also benefit from sunk capital and established operating routines, which makes replacement cycles more gradual and raises switching costs once automation tracks are in place. In the AI-integrated blood analyzers market, the installed foundation gives leading suppliers a stable revenue base from analyzers, reagents, maintenance, and software upgrades.

Semi-Automated Systems continue to serve mid-volume laboratories that need dependable 5-part differential capability but cannot justify a full workcell buildout. The segment is gradually losing ground from both sides because affordable compact devices pressure it at the lower end, while leasing and scaling programs pull higher-volume sites toward full automation. Point-of-Care Systems are the fastest-growing modality with a 16.63% CAGR through 2031, and that pace reflects more than instrument miniaturization. The AI-integrated blood analyzers market is therefore widening not only across large laboratories, but also across urgent care, ambulatory, and remote settings where near-patient testing can shorten clinical decision time. This dynamic broadens the addressable need of the AI-integrated blood analyzers market without removing the operational importance of high-throughput central sites.

AI-integrated Blood Analyzers controlled 47.14% of product-type revenue in 2025, which kept core analyzer hardware at the center of the AI-integrated blood analyzers market. That leading share came from the global installed base built by large manufacturers such as Sysmex, Beckman Coulter, and Siemens Healthineers, whose high-throughput analyzer lines remain the base layer for routine complete blood count testing. Hardware still matters because analyzer contracts often anchor reagent pull-through, service agreements, and workflow standardization inside large laboratory accounts. AI Digital Morphology Analyzers remain the most differentiated hardware category because they address one of the most labor-intensive parts of blood review and allow subtle abnormalities to be reviewed in a more structured way. AI-Integrated Point-of-Care Blood Analyzers are also gaining visibility because compact formats can extend testing access into settings that do not have full laboratory infrastructure.

AI Blood Analysis Software is the fastest-growing product type, and the AI-integrated blood analyzers market size for this segment is projected to expand at a 17.16% CAGR through 2031. That growth is important because software can be deployed as a service layer, updated more often than hardware, and added to existing instrument fleets without forcing a full replacement cycle. Software monetization as the main value creation shift in the market, which means the revenue center is moving from one-time equipment purchase toward recurring analytics, decision support, and workflow modules. Within the AI-integrated blood analyzers industry, this makes installed-base access more valuable than pure instrument shipment volume. It also explains why suppliers are investing in digital morphology, connectivity, and remote review functions that can sit on top of existing analyzer footprints. As this pattern deepens, the AI-integrated blood analyzers market is likely to see stronger competition around image interpretation, flagging algorithms, and service contracts than around analyzer mechanics alone.

Complete Report Scope:

• By Modality
  • Fully Automated Systems
  • Semi-Automated Systems
  • Point-of-Care Systems
• By Product Type
  • AI-Integrated Hematology Analyzers
  • AI-Integrated Point-of-Care Blood Analyzers
  • AI-Based Digital Morphology Analyzers
  • AI Blood Analysis Software
• By Application
  • Complete Blood Count Testing
  • Anemia Screening and Triage
  • Blood Cancer Diagnostics
  • Infection Detection
  • Hemorrhagic Condition Monitoring
  • Digital Morphology and Peripheral Smear Review
  • Others (Prenatal and Neonatal Testing, Wellness & Preventive Health, etc.)
• By End User
  • Hospitals
  • Diagnostic Laboratories
  • Blood Banks and Transfusion Centers
  • Ambulatory and Urgent Care Centers
  • Research and Academic Institutes
  • Others (Mobile Diagnostic Units, Dialysis Centers, etc.)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 42.36% of the AI-integrated blood analyzers market share in 2025, which kept it as the largest regional contributor. The region benefits from a dense base of high-throughput reference laboratories, established reimbursement structures for in vitro diagnostics, and a regulatory pathway that is increasingly familiar with AI-enabled hematology devices. In the United States, laboratory consolidation and staff shortages continue to support demand for automation because larger networks want more throughput and more consistent review quality from fewer specialized personnel. The FDA clearance pathway is also shaping supplier behavior, as shown by the Sysmex XR-Series clearance under the relevant automated blood analyzer classification and the steady push toward next-generation systems with more integrated analytics. Canada and Mexico remain smaller but important contributors, with Canada favoring networked digital review models and Mexico offering room for mid-tier analyzer uptake through its growing private diagnostic laboratory base.

Asia-Pacific is the fastest-growing region, and the AI-integrated blood analyzers market size in the region is forecast to expand at a 15.32% CAGR through 2031. The region is diverse because China combines large import demand with stronger domestic manufacturing, while Japan and South Korea maintain deeper capability in advanced laboratory instrumentation and premium clinical workflows. Mindray's hematology push and its total laboratory automation cooperation with Inpeco show how local and regional suppliers are trying to deepen their position not only through analyzers, but also through connected laboratory ecosystems. India's demand profile is tied closely to diagnostic laboratory expansion and higher screening needs for blood disorders, which makes scalable analyzer deployment especially relevant outside major hospital systems. In July 2026, ASUS Blade received Health Sciences Authority approval in Singapore for AI-powered peripheral blood film analysis software, which signals that Southeast Asia is becoming a useful early-adoption and validation point for AI morphology tools.

Europe remains an important revenue base for the AI-integrated blood analyzers market because accreditation expectations and digital laboratory practices support the adoption of AI-assisted review, especially in Germany, France, the United Kingdom, and the Nordic countries. The region's stricter regulatory and compliance environment creates more work for vendors, but it also favors suppliers that can document performance, oversight, and quality control in a structured way.

1. Abbott Laboratories
2. Beckton Dickinson
3. Bio-Rad Laboratories
4. Boule Diagnostics
5. CellaVision AB
6. Danaher
7. Diatron MI PLC
8. EKF Diagnostics Holdings plc
9. Roche
10. HemoCue AB
11. HORIBA
12. Mindray
13. Nihon Kohden
14. Ortho Clinical Diagnostics
15. PixCell Medical Technologies Ltd.
16. Scopio Labs Ltd.
17. Siemens Healthineers
18. Sight Diagnostics Ltd.
19. Sysmex
20. Transasia Bio-Medicals Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Demand for AI-Assisted Morphology Review
  • 4.2.2 Expansion of Fully Automated High-Throughput Labs
  • 4.2.3 Rising Blood Disorder Screening Volumes
  • 4.2.4 Decentralized Testing Needs in Acute and Urgent Care
  • 4.2.5 Increasing LIS and Digital Workflow Integration
• 4.3 Restraints
  • 4.3.1 High Instrument and Per-Test Cost Burden
  • 4.3.2 Validation Gaps Versus Central Laboratory Standards
  • 4.3.3 Data Privacy and Cybersecurity Compliance Complexity
  • 4.3.4 Shortage of Skilled Hematology Review Personnel
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

• 5.1 By Modality
  • 5.1.1 Fully Automated Systems
  • 5.1.2 Semi-Automated Systems
  • 5.1.3 Point-of-Care Systems
• 5.2 By Product Type
  • 5.2.1 AI-Integrated Hematology Analyzers
  • 5.2.2 AI-Integrated Point-of-Care Blood Analyzers
  • 5.2.3 AI-Based Digital Morphology Analyzers
  • 5.2.4 AI Blood Analysis Software
• 5.3 By Application
  • 5.3.1 Complete Blood Count Testing
  • 5.3.2 Anemia Screening and Triage
  • 5.3.3 Blood Cancer Diagnostics
  • 5.3.4 Infection Detection
  • 5.3.5 Hemorrhagic Condition Monitoring
  • 5.3.6 Digital Morphology and Peripheral Smear Review
  • 5.3.7 Others (Prenatal and Neonatal Testing, Wellness & Preventive Health, etc.)
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Diagnostic Laboratories
  • 5.4.3 Blood Banks and Transfusion Centers
  • 5.4.4 Ambulatory and Urgent Care Centers
  • 5.4.5 Research and Academic Institutes
  • 5.4.6 Others (Mobile Diagnostic Units, Dialysis Centers, etc.)
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 Beckman Coulter, Inc.
  • 6.3.3 Bio-Rad Laboratories, Inc.
  • 6.3.4 Boule Diagnostics AB
  • 6.3.5 CellaVision AB
  • 6.3.6 Danaher Corporation
  • 6.3.7 Diatron MI PLC
  • 6.3.8 EKF Diagnostics Holdings plc
  • 6.3.9 F. Hoffmann-La Roche Ltd
  • 6.3.10 HemoCue AB
  • 6.3.11 HORIBA, Ltd.
  • 6.3.12 Mindray Medical International Limited
  • 6.3.13 Nihon Kohden Corporation
  • 6.3.14 Ortho Clinical Diagnostics
  • 6.3.15 PixCell Medical Technologies Ltd.
  • 6.3.16 Scopio Labs Ltd.
  • 6.3.17 Siemens Healthineers AG
  • 6.3.18 Sight Diagnostics Ltd.
  • 6.3.19 Sysmex Corporation
  • 6.3.20 Transasia Bio-Medicals Ltd.

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

• 7.1 White-Space and Unmet-Need Assessment